CompletedNot applicableNCT04953065

Coronavirus Disease 2019 (COVID-19) Vaccination in Cancer Patients

The current study primarily aims to determine the status of vaccination in enrolled cancer patients and identify barriers to coronavirus disease 2019 (COVID-19) vaccination in cancer patients who have not been vaccinated. Secondary objectives include determining the rate of vaccination in those who have ever been COVID-19 positive and those who have never been COVID-19 positive. The study team also seeks to determine factors associated with vaccine-acceptance and vaccine-hesitancy in the adult cancer population, identify side effects of COVID-19 vaccines in vaccinated cancer patients and to examine the effect of COVID-19 vaccination on overall clinical outcome in cancer patients. The study team will be conducting telephone interviews/surveys with up to130 adult cancer patients for data collection.

Checked against the public recordLast updated May 9, 2024 · Source: ClinicalTrials.gov

StatusCompleted
PhaseNot applicable
U.S. locations1
SponsorMonika Joshi
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Monika Joshi
Interventions being studied
Other: COVID-19 vaccine hesitancy and acceptance survey
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. Current or past medical history of invasive malignancy (any type) that has been treated at PSCI 2. Patients who are at least 18-years-old and younger than 90-years-old 3. Patients need to have working telephone /ability to converse. Interpreter could be used to get help with survey if not English speaking. 4. Patients who have had previous COVID-19 infection are also eligible. Exclusion Criteria: 1. Patients who have not been treated or have been seen for current or past medical history of invasive malignancy (any type) at Penn State Cancer Institute 2. Patients who are under the age of 18 and older than 89-years-old 3. Patients who cannot provide consent

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Penn State Cancer InstituteHershey, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 9, 2024. Always confirm current availability with the study team.

View original record ↗